Temporary Tear Duct Filling With Hyaluronic Acid Gel and Assessment of Dry Eye Disease (DED) After Bilateral Cataract Surgery (TANAMI)
Temporary Tear Duct Filling With Hyaluronic Acid Gel and Assessment of Dry Eye Disease (DED) After Bilateral Cataract Surgery in a Prospective Randomized Controlled Inter-eye Study
Dry eye disease can occur or worsen after cataract surgery and may cause ocular discomfort and reduced visual quality. Standard treatment commonly includes artificial tear eye drops, which provide temporary lubrication. Temporary occlusion of the tear drainage system may offer an alternative approach by increasing tear retention and improving tear film stability.
This prospective, randomized, double-blind, inter-eye study will evaluate the use of LACRIFILL® Canalicular Gel, a crosslinked hyaluronic acid gel placed in the tear drainage system, in patients who have undergone bilateral cataract surgery. Treatment allocation will be randomized at the eye level within each participant. One eye will be assigned to treatment with LACRIFILL®, while the fellow eye will serve as the control and receive standard care with artificial tear eye drops.
The study will compare the development and severity of dry eye disease between the randomized treatment and control eyes. The main outcome will be tear production measured by the Schirmer Test 1 one month after treatment. Additional assessments will include tear film stability, ocular surface findings, anterior segment imaging, visual quality, dry eye symptoms, use of artificial tears, and treatment-related safety outcomes during a three-month follow-up period.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
State of Vienna
-
Vienna, State of Vienna, Austria, 1090
- Medical University of Vienna, Department of Ophthalmology and Optometry
-
Contact:
- Gregor S. Reiter, MD, PhD, BA, MSc
- Phone Number: +43 1 40400 73419
- Email: gregor.reiter@meduniwien.ac.at
-
Contact:
- Johannes Schrittwieser, MD
- Phone Number: +43 1 40400 73557
- Email: johannes.schrittwieser@meduniwien.ac.at
-
Principal Investigator:
- Gregor S. Reiter, MD, PhD, BA, MSc
-
Sub-Investigator:
- Johannes Schrittwieser, MD
-
Sub-Investigator:
- Markus Schranz, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Uncomplicated bilateral cataract surgery for age-related cataract within the last 2-7 days
- Implantation of the same type of lens in both eyes (diopters may differ).
- Age 45-99 years
- Willingness to complete the study
- Signed informed consent form
Exclusion Criteria:
- Bilateral cataract due to a different cause
- Retinal findings affecting quality of life or visual acuity in any eye
- History of uncontrolled glaucoma in any eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma mediation)
- Active or suspected ocular or periocular infection in the study eye.
- Vitreous hemorrhage or history of rhegmatogenous retinal detachment or macular hole in the study eye.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: LACRIFILL® Canalicular Gel Lacrimal Occlusion
Within each participant, one eye will be randomly assigned to receive a single intracanalicular administration of LACRIFILL® Canalicular Gel into the lower canaliculus.
The intervention is intended to provide temporary occlusion of the lacrimal drainage system and thereby reduce tear drainage and increase tear retention.
The fellow eye will serve as the control eye.
|
LACRIFILL® Canalicular Gel is a crosslinked hyaluronic acid hydrogel administered intracanalicularly into the lower canaliculus.
Approximately 0.2 mL is administered as a single application to the randomized treatment eye to achieve temporary occlusion of the lacrimal drainage system.
|
|
Sham Comparator: Lacrimal Irrigation
The fellow eye of each participant will undergo lacrimal irrigation as a sham procedure.
No LACRIFILL® Canalicular Gel will be administered to the control eye.
The control eye will otherwise receive standard postoperative care, including artificial tear supplementation, according to standard clinical practice.
|
Lacrimal irrigation performed as a sham procedure in the control eye without administration of LACRIFILL® Canalicular Gel or temporary canalicular occlusion.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Inter-eye difference in Schirmer Test 1 at month 1
Time Frame: 1 months
|
Difference in Schirmer Test I tear production between the Lacrifill-treated eye and the contralateral standard-of-care eye at 1 month after cataract surgery.
Schirmer Test I measures tear production as the length of wetting of a standardized filter paper strip over 5 minutes, expressed in millimeters (mm).
Values for each eye range from 0 to 35 mm, with higher values indicating greater tear production.
The inter-eye difference is calculated as the Schirmer Test I value in the Lacrifill-treated eye minus the value in the standard-of-care eye, resulting in a possible range of -35 to +35 mm.
Positive values indicate greater tear production in the Lacrifill-treated eye.
|
1 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Inter-eye difference in Schirmers Test 1 at month 3
Time Frame: 3 Months
|
Difference in Schirmer Test I tear production between the Lacrifill-treated eye and the contralateral standard-of-care eye at 3 month after cataract surgery.
Schirmer Test I measures tear production as the length of wetting of a standardized filter paper strip over 5 minutes, expressed in millimeters (mm).
Values for each eye range from 0 to 35 mm, with higher values indicating greater tear production.
The inter-eye difference is calculated as the Schirmer Test I value in the Lacrifill-treated eye minus the value in the standard-of-care eye, resulting in a possible range of -35 to +35 mm.
Positive values indicate greater tear production in the Lacrifill-treated eye.
|
3 Months
|
|
Inter-eye difference in Oxford grading at month 1 and months 3
Time Frame: 1 month, 3 months
|
Difference in ocular surface staining between the Lacrifill-treated eye and the contralateral standard-of-care eye at 1 and 3 months after cataract surgery, assessed using the Oxford Scheme for Ocular Surface Staining.
The Oxford score ranges from 0 to 5 for each eye, with higher scores indicating greater ocular surface staining and therefore a worse outcome.
The inter-eye difference is calculated as the Oxford score in the Lacrifill-treated eye minus the score in the standard-of-care eye, resulting in a possible range of -5 to +5.
Negative values indicate less ocular surface staining, and therefore a better outcome, in the Lacrifill-treated eye.
|
1 month, 3 months
|
|
Inter-eye difference in tear break up time (TBUT) at month 1 and 3
Time Frame: 1 month; 3 months
|
Difference in Tear Film Break-Up Time (TBUT) between the Lacrifill-treated eye and the contralateral standard-of-care eye at 1 and 3 months after cataract surgery.
TBUT is measured in seconds and represents the time between a complete blink and the first appearance of a break in the tear film.
Higher TBUT values indicate greater tear film stability and therefore a better outcome.
The inter-eye difference is calculated as the TBUT in the Lacrifill-treated eye minus the TBUT in the standard-of-care eye; positive values indicate greater tear film stability in the Lacrifill-treated eye.
|
1 month; 3 months
|
|
Non-invasive tear break-up time measured with the MS-39 at Months 1 and 3
Time Frame: 1 month; 3 months
|
Tear film stability will be assessed using the first non-invasive tear break-up time (NIBUT) measured with the MS-39 anterior segment analyzer (CSO, Florence, Italy).
The integrated Placido disk-based tear film analysis detects the time from the last blink to the first detected disruption of the tear film.
NIBUT is recorded in seconds.
Higher values indicate greater tear film stability and therefore a better outcome.
Measurements will be performed separately in the Lacrifill-treated eye and the contralateral sham-treated eye.
|
1 month; 3 months
|
|
Halo/glare size measured with the Real Artificial Lens Vision (RALV) system
Time Frame: 1 month and 3 months
|
Halo/glare size will be quantitatively assessed using the Real Artificial Lens Vision (RALV) halo/glare test.
Participants view a central white light source while optotypes are presented at decreasing radial distances from the light source.
Halo/glare size is recorded as angular extent in milliradians (mrad).
Higher values indicate a larger halo/glare phenomenon and therefore greater visual disturbance.
Measurements will be performed separately for the Lacrifill-treated eye and the contralateral sham-treated eye.
|
1 month and 3 months
|
|
Outcomes of questionnaires
Time Frame: 1 month; 3 months
|
Report of the dry eye disease questionnaires (OSDI and SPEED) and the National Eye Institute Visual function questionnaire 25 at month 1 and 3
|
1 month; 3 months
|
|
Number of applied artifical tear drops
Time Frame: 3 months
|
Self-reported number of average applications of artificial tear drops per eye per day.
|
3 months
|
|
Incidence of adverse events and device- or procedure-related adverse events
Time Frame: 3 months
|
Incidence, nature, severity, and relationship to the investigational device and/or procedure of adverse events, including serious adverse events and serious adverse device effects.
|
3 months
|
|
Inter-eye difference in visual quality assessment
Time Frame: 1 month; 3 months
|
Difference in Visual quality assessment measured by Refractive Artificial Lens Vision (RALV) at month 1 and 3
|
1 month; 3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1058/2026
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.